Skip to main content

Vaxneuvance Side Effects

Generic name: pneumococcal 15-valent conjugate vaccine

Medically reviewed by Drugs.com. Last updated on Sep 6, 2022.

Note: This document contains side effect information about pneumococcal 15-valent conjugate vaccine. Some dosage forms listed on this page may not apply to the brand name Vaxneuvance.

Applies to pneumococcal 15-valent conjugate vaccine: intramuscular suspension.

Serious side effects of Vaxneuvance

Along with its needed effects, pneumococcal 15-valent conjugate vaccine (the active ingredient contained in Vaxneuvance) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking pneumococcal 15-valent conjugate vaccine:

Less common

Other side effects of Vaxneuvance

Some side effects of pneumococcal 15-valent conjugate vaccine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
  • decreased appetite
  • difficulty in moving
  • headache
  • joint pain or swelling
  • muscle aches, cramps, pains, or stiffness
  • unusual tiredness or weakness

For Healthcare Professionals

Applies to pneumococcal 15-valent conjugate vaccine: intramuscular suspension.

Dermatologic

Frequency of rash was common in infants.

Common (1% to 10%): Rash, urticaria

Gastrointestinal

Common (1% to 10%): Nausea, vomiting

Vomiting was more common in infants.

General

The most common adverse events were injection site pain, myalgia, fatigue, injection site swelling and erythema, and arthralgia.[Ref]

Hypersensitivity

Hypersensitivity reactions were reported in adults.

Rare (0.01% to 0.1%): Hypersensitivity reaction (including tongue edema, flushing, and throat tightness)

Local

Very common (10% or more): Pain (66.8% to 75.8%), erythema (10.9% to 15.1%)

Common (1% to 10%): Injection site bruising/hematoma, pruritus

Uncommon (0.1% to 1%): Injection-site urticaria, warmth

Frequency not reported: Induration, swelling[Ref]

Metabolic

Very common (10% or more): Decreased appetite

Decrease in appetite was very common in infants aged less than 2 years than children of greater than 2 years of age.

Musculoskeletal

Very common (10% or more): Arthralgia (7.7% to 12.7%), myalgia (26.9% to 28.8%)[Ref]

Nervous system

Very common (10% or more): Headache (18.9% to 26.5%)

Uncommon (0.1% to 1%): Dizziness

Frequency not reported: Somnolence[Ref]

Somnolence was very common in infants.[Ref]

Other

Very common (10% or more): Fatigue (21.5% to 34.3%)

Common (1% to 10%): Fever

Uncommon (0.1% to 1%): Chills[Ref]

Psychiatric

Irritability was very common in infants aged less than 2 years of age.

Very common (10% or more): Irritability

More about Vaxneuvance (pneumococcal 15-valent conjugate vaccine)

Patient resources

Professional resources

Related treatment guides

References

1. "Product Information. Vaxneuvance (pneumococcal 15-valent conjugate vaccine)." Merck & Company Inc (2021):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.